875 related articles for article (PubMed ID: 10918407)
1. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
2. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Hale G; Waldmann H
Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
[TBL] [Abstract][Full Text] [Related]
3. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
[TBL] [Abstract][Full Text] [Related]
5. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
6. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
[TBL] [Abstract][Full Text] [Related]
7. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
Norlin AC; Remberger M
Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
Hamblin M; Marsh JC; Lawler M; McCann SR; Wickham N; Dunlop L; Ball S; Davies EG; Hale G; Waldmann H; Gordon-Smith EC
Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
[TBL] [Abstract][Full Text] [Related]
11. CAMPATH-1 antibodies in stem-cell transplantation.
Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
13. Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
Cobbold SP; Hale G; Clark MR; Waldmann H
Prog Clin Biol Res; 1990; 333():139-51; discussion 152-4. PubMed ID: 2308978
[TBL] [Abstract][Full Text] [Related]
14. Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation.
Chakraverty R; Robinson S; Peggs K; Kottaridis PD; Watts MJ; Ings SJ; Hale G; Waldmann H; Linch DC; Goldstone AH; Mackinnon S
Bone Marrow Transplant; 2001 Nov; 28(9):827-34. PubMed ID: 11781642
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.
Barge RM; Starrenburg CW; Falkenburg JH; Fibbe WE; Marijt EW; Willemze R
Bone Marrow Transplant; 2006 Jun; 37(12):1129-34. PubMed ID: 16757974
[TBL] [Abstract][Full Text] [Related]
16. Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity.
Condiotti R; Nagler A
Bone Marrow Transplant; 1996 Oct; 18(4):713-20. PubMed ID: 8899185
[TBL] [Abstract][Full Text] [Related]
17. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
18. CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Hale G; Waldmann H
J Hematother; 1994; 3(1):15-31. PubMed ID: 7922004
[TBL] [Abstract][Full Text] [Related]
19. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
Trzonkowski P; Zilvetti M; Friend P; Wood KJ
Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
[TBL] [Abstract][Full Text] [Related]
20. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.
Kim HJ; Park CY; Park YH; Kim YJ; Kim DW; Min WS; Kim CC
Bone Marrow Transplant; 2003 Jan; 31(2):79-86. PubMed ID: 12621487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]